|  | 
                        
                        |  |  
                        |  |  
                        |  | 
	
	IQ 577® Laser System – True yellow laser for retinal disorders. MicroPulse® Laser Therapy for Fovea-Friendly™* laser grids and tissue-sparing* combo therapies. PRODUCT HIGHLIGHTS
    High transmission through dense ocular mediaDual Port for efficient setup of alternate delivery devicesRepeatable macular and foveal laser sessionsMaximize workflow efficiency Learn How | 
	
	
Schedule a hands-on demoSchedule a no-obligation demo to see for yourself how MicroPulse Technology and Iridex’s Family of Products can take YOUR practice to the next level. |  
                        | 
                        
                        | 
	
 True Yellow, 577nm wavelength for precise performance  High transmission through dense ocular media Consistent laser lesions for fast procedure time Low power required for increased patient comfort Intelligent and intuitive design Dual Port for efficient setup of alternate delivery devices Intuitive graphic touch screen interface for ease of use Programmable memory presets for multiple users  Optional Module for MicroPulse Laser Therapy Repeatable macular and foveal laser sessions Success with refractory and sub-clincal edema   
    
        
        
            | Wavelength | 577 nm Yellow |  
            | Weight | 19.2 lb (9.0 kg) |  
            | Dimensions | 8.5" H x 12" W x 14" D (21 cm x 30 cm x 35 cm)
 |  
            | Connector Type 
 | RFID | Resistor |  
            | Electrical | 100-240 VAC, 50/60 Hz 
 |  
            | Cooling | Whisper fan |  
            | Exposure Duration | CW-Pulse: 10-3000 ms |  
            | Exposure Interval | CW-Pulse: 10-3000 ms |  
            | MicroPulse Duration | MicroPulse: 0.05-1.00 ms |  
            | MicroPulse Interval | MicroPulse: 1.00-10.00 ms |  
            | Aiming Laser | Diode laser, 635 nm nominal |  
            | Delivery Device Power Output | Portable SLA: 0-2000 mW LIO: 0-2000 mW
 EndoProbe: 0-2000 mW
 |   
    
        
            |  |  | IQ 577 Laser Video  |  
            |  |  | Tratamiento de Retina con el Laser IQ 577  |  
            |  |  | Testimonial Dr Sergio Rojas  |  
            |  |  | MicroPulse for when injections are not enough - Dr. Marco Zarbin  |  
            |  |  | Successful MicroPulse Treatment for Macular Edema in Retinal Vein Occlusion  |  
            |  |  | Iridex MicroPulse ESCRS 2018 Symposium Q&A  |  
            |  |  | Iridex at the American Academy of Ophthalmology 2018  |  
            |  |  | Tratamiento Para la Retina con Láser MicroPulse de Iridex - Dr. Munir Escaf  |  
            |  |  | The Role of Laser Therapy in the Treatment of Retinal Diseases  |  
            |  |  | Long-term follow-up of 577 nm micropulse laser for central serous chorioretinopathy - Dr. Andre Maia  |  
            |  |  | IQ 577  |   
This page is currently being updated. In the meantime, for any information you are looking for, please contact info@iridex.com  Optional AccessoriesFull-Featured Remote Control 
    Compact design for easy placement or use in sterile field View displays and adjust parameters from two vantage points for increased convenience and efficiency Wireless Footswitch
    No cord, no clutter, no limitations Allows precise physician control over power settingsAvailable with power-adjust to control laser actuation and power settings                           | Munir Escaf, MDRetina SpecialistClinica Carriazo Barranquilla
 Atlantico, Columbia
 |  |              | Jonathan Feistman, MDRetina SpecialistNYC Retina
 New York City, NY
 |  |              | Brian Horsman, MDDirector, Retina GroupBarnet Dulaney Perkins Eye Center
 Phoenix, AZ USA
 |  |              | Brandon Johnson, MDNYC RetinaNew York, NY USA
 |  |              | Ahad Mahootchi, MDMedical DirectorThe Eye Clinic of Florida
 Zephyrhills, FL
 |  |              | Walid Mangal, DOFlorida Vision InstituteStuart, FL USA
 |  |                          | "By incorporating MicroPulse, my injection burden decreases by one-third at a minimum, which is a conservative estimate. The versatility of MicroPulse to treat retinal disorders and glaucoma allows me to provide my patients with a treatment that’s clinically effective, cost effective, and time effective.""MLT is both safe and durable. This therapy can be considered a first-line treatment for glaucoma patients, as well as patients who haven’t seen significant effects from medications." Jason Friedrichs, MD, MSFriedrichs Eye
 Sycamore, IL USA
 | "The MicroPulse P3 Device has become an essential part of my armamentarium for use in glaucoma surgical procedures. It provides a very safe and efficacious solution for IOP control. I have used MicroPulse P3 for some of my most complicated cases but also I feel comfortable enough using it for patients with earlier disease in which we want to avoid a filtering bleb or the placement of hardware in the eye." Robert Noecker, MD, MBAOphthalmic Consultants of Connecticut
 Fairfield, CT USA
 |                      | "I have found the MicroPulse P3 Device to be a non-incisional, easy, and safe way to reduce pressure anytime my patients need it, and it is predictable and highly efficacious." Melissa Toyos, MDToyos Clinic
 Nashville, TN USA
 | "MLT is both safe and durable. This therapy can be considered a first-line treatment for glaucoma patients, as well as patients who haven’t seen significant effects from medications." Ike Ahmed, MD, FRCSCPrism Eye Institute
 Toronto, Ontario, Canada
 | "I have been impressed that the MicroPulse P3 therapy with the Cyclo G6 Glaucoma Laser can deliver pressure lowering in a broad range of glaucomas, including mild and moderate patients who I want to free from the adverse effects of drops." Rolando Toyos, MDToyos Clinic
 Nashville, TN USA
 |              | "The visualization of the ciliary body and the surrounding area is impressive. It has really helped me to deliver a patient-specific, targeted CPC treatment with an easy-to-use probe." Steven Vold, MDVold Vision
 Fayetteville, AR USA
 |              | "You can really consider TSCPC in almost all glaucoma situation, even malignant glaucoma. It is not just relegated to end-stage treatment anymore." Dr. Jeffrey KammerVanderbilt Eye Institute
 Nashville, TN
 | "TSCPC is a surgery that can be done before or after any other surgery. It is very versatile from that standpoint. " Nathan Radcliffe, MD
 New York Eye Surgery Center
 Bronx, NY USA
 | "Recovery with TSCPC is much more rapid and the postoperative care much less involved than with someone who has had an incisional glaucoma case in a surgical center." Steven Vold, MD
 Vold Vision
 Fayetteville, AR USA
 |                          | Lawrence Morse, MD, PhDUC DavisDavis, CA USA
 |  |              | Kishiko Ohkoshi, MDProfessor, Director, Chief Vitreoretinal SurgeonSt. Luke’s International University
 Tokyo, Japan
 |  |              | Julia Schulman, MD NYC Retina
 New York, NY USA
 |  |              | Stela Vujosevic, MD Professor, Medial Retina SpecialistUniversity Hospital Maggiore della Carita
 Novara, Italy
 |  |              | Glenn Yiu, MD, PhDUC DavisDavis, CA USA
 |  |              | Marco Zarbin, MD, PhD, FACSRutgers New Jersey Medical SchoolNewark, NJ USA
 |  |  MLT Focused                        | "I achieved such good results with MLT that I decided to try MicroPulse for treating retinal diseases. I now use it daily to treat many retinal disorders, and MicroPulse allows me to treat patients who I could not have otherwise." Brandon Philips, MDCarolina Vision Center
 Fayetteville, NC USA
 | "MLT is versatile in variety of ways: for patients just starting therapy, replacing an eye drop, as an adjunct to an eye drop or to keep them away from incisional surgery." Nathan Radcliffe, MDNew York Eye Surgery Center
 Bronx, NY USA
 | "The IQ 577 Laser produces less collateral damage than a traditional green-wavelength laser during the treatment of macular edema. It's more efficient and increases patient comfort for panretinal photocoagulation." Jonathan Walker, MDLutheran Hospital of Indiana
 Fort Wayne, IN USA
 |                          | "The IQ 577 Laser System has simplified and improved the efficiency of laser clinics dramatically." Christopher Riemann, MDCincinnati Eye Institute
 Cincinnati, OH USA
 | "The IQ 577 Laser System with yellow laser is one such promising advancement for the treatment of macular edema." Sviatoslav Suk, MD, PhDEye Microsurgery CenterKiev, Ukraine |   September 11, 2019: MicroPulse® Transscleral Laser Therapy Will be Discussed in Various Presentations and Educational Events at ESCRS 2019 in Paris, France June 3, 2019: Laser treatment for DME: Still a place at the table May 1, 2019: Study shows MicroPulse Laser controls IOP after Keratoplasty April 29, 2019: MicroPulse Laser featured in several Glaucoma and Retina research presentations at Ophthalmic Industry Conferences April 10, 2019: Meet MicroPulse TSCPC Experts at ASCRS in San Diego on May 4-6, 2019 April 8, 2019: ASCRS Breakfast: MicroPulse TSCPC as a Treatment for Failed MIGS Procedures April 1, 2019: The Role of Laser for Retinal Vascular Disease in the Anti-VEGF Era April 1, 2019: MicroPulse featured in multiple abstracts, posters, and presentations at WGC March 1, 2019: How does wavelength factor into choosing a laser? by Caesar Luo, MD January 14, 2019: Subthreshold Laser Treatment for Macular Edema by Matteo Forlini, MD June 25, 2018: Iridex Announces Multiple Studies of MicroPulse® Laser Therapy Published at World Ophthalmology Congress May 17, 2018: Iridex MicroPulse Technology Featured In Many Scientific Presentations at the European Glaucoma Society Meeting May 02, 2018: Iridex Announces Dramatic Increase In MicroPulse Visibility at the 2018 ARVO Meeting September 06, 2017: Iridex Explored on Innovations Breakthrough Series |  |  |  
                        | 
	
	
*Bhagat N, Zarbin M, Mansour S, Chong V, and Cardillo JA. Fovea-friendly MicroPulse Laser. Supplement to Retina Today, May/June 2012 |  |  |